<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581085</url>
  </required_header>
  <id_info>
    <org_study_id>1807361301</org_study_id>
    <nct_id>NCT02581085</nct_id>
  </id_info>
  <brief_title>Tocotrienol Against the Progression of End Stage Liver Disease</brief_title>
  <official_title>Tocotrienol Against the Progression of End Stage Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaysia Palm Oil Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial
      that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end
      stage liver disease / cirrhosis. The study is double blind and participants will be
      randomized to take 2 capsules of TCT (200mg) or placebo twice a day for 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tocotrienol (TCT) is a natural vitamin E supplement with a long history of safe dietary
      consumption. Prior studies with Vitamin E have shown beneficial effects in patients with
      non-alcoholic fatty liver disease and cirrhosis. The primary purpose of this Phase 2 trial is
      to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in
      MELD (Model For End-Stage Liver Disease) score over time in patients with cirrhosis. Outcomes
      of this trail will direct the design of a future larger multi-center trial.

      Study participation will last 3 years. Subjects will be seen for an initial visit, at which
      consent will be obtained and baseline labs drawn, followed by a Randomization visit 2-14 days
      later after MELD criteria have been confirmed. If the acceptable labs have not been drawn per
      standard of care to calculate a MELD score within 90 days before the initial visit, the
      subject will complete the initial visit as planned, but will then return for a repeat lab
      draw 60 days later to confirm MELD criteria for eligibility before continuing to the
      randomization visit.

      Enrollment occurs when a subject meets all criteria and is randomized into one of the
      treatment groups. Subjects will then be seen in the research office by research personnel at
      1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, 1 year, 18 months, 2 years,
      and 3 years. Subject compliance with supplements will be closely followed, as compliance is
      critical for accurate data. Given the small sample size, subjects who are less than 75%
      compliant at two consecutive study visits will be discontinued from the study. Subjects will
      be discontinued if their MELD score increases by more than 25% between 2 consecutive visits
      or if they receive an organ transplant. Subjects will be declared lost to follow-up (LTFU) if
      a study visit is unable to be scheduled and completed after 4 documented attempts to contact
      a subject with no response. In this circumstance, a certified letter will be mailed to the
      subject's last known address; if no response is received, the subject is LTFU. All subjects
      discontinued or LTFU before the end of 1 year of study participation will be replaced (see
      protocol to review study visit activities that will occur). At the Randomization Visit,
      enrolled subjects will be randomized into one of two treatment groups in a 1:1 manner. Group
      1: Placebo vehicle; (2) placebo capsules following AM meal, (2) placebo capsules following PM
      meal Group 2: 800mg TCT; (2) 200mg TCT capsules following AM meal, (2) 200mg TCT capsules
      following PM meal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Oral tocotrienols (TCT) on Model for End-Stage Liver Disease (MELD) score.</measure>
    <time_frame>3 years</time_frame>
    <description>Lab tests to calculate MELD score will be taken at baseline study visit and the last study visit ( Study visit 8 - 3 years) to see if Oral TCT will significantly attenuate the rise in MELD score over time in patients with End Stage Liver Disease / Cirrhosis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>End Stage Liver Disease</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>NAFLD - Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocotrienol supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocotrienol (TCT)</intervention_name>
    <description>TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.</description>
    <arm_group_label>Tocotrienol supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control study capsule that includes no study product (Vitamin E - Tocotrienol)</description>
    <arm_group_label>Placebo Vehicle</arm_group_label>
    <other_name>vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years of above, male or female

          -  ESLD patients with clinically- diagnosed NAFLD or NASH

          -  Absence of any other possible cause for liver dysfunction

          -  Stable MELD score of at least 8, but no greater than 15 over the past 6 months (+/- 1
             month) prior to enrollment

          -  Able to speak and understand English

          -  Willing and able to provide informed consent

          -  Willing and able to return for regularly scheduled research study visits &amp; comply with
             study requirements

        Exclusion Criteria:

          -  Rapid deterioration of liver function, over the past 6 months (+/- 1 month) prior to
             enrollment per study physician determination

          -  Hepatocellular carcinoma

          -  Positive HIV/ AIDS, or other chronic immunodeficiency

          -  Concurrent hepatitis A or B infection

          -  Current drug and/or alcohol abuse (per treating physician)

          -  Bacterial infection at time of enrollment

          -  Daily use of dedicated vitamin E supplementation within the 12 months prior to study
             participation

          -  Platelets &lt;25,000 cells/µL, neutrophils &lt;1000 cells/µL, hemoglobin &lt;8g/dL, total
             bilirubin &gt;3mg/dL, serum creatinine &gt;2.0mg/dL

          -  Women who are pregnant, breastfeeding, or plan to become pregnant during course of
             study participation (36 months)

          -  Other significant comorbidities which limit the subject's life expectancy to less than
             36 months

          -  Patients receiving medications known to treat Hepatitis C; patients who begin taking
             these medications during the course of study participation will be dropped.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandan K Sen, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raj Vuppalanchi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Unviersity School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Mohnacky, RN</last_name>
    <phone>317-278-2715</phone>
    <email>jmohnack@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sashwati Roy, Ph.D</last_name>
    <phone>3172782706</phone>
    <email>roysa@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IU Health Unviersity Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Adams, RN</last_name>
      <phone>317-962-1130</phone>
      <email>hejadams@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessie Vaughn, RN</last_name>
      <phone>317-274-8427</phone>
      <email>jevaughn@iu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, Shneker B, Ganesh K, Phillips G, More JL, Sarkar A, Kirkpatrick R, Elkhammas EA, Klatte E, Miller M, Firstenberg MS, Chiocca EA, Nesaretnam K, Sen CK. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012 Mar;142(3):513-9. doi: 10.3945/jn.111.151902. Epub 2012 Feb 1.</citation>
    <PMID>22298568</PMID>
  </reference>
  <reference>
    <citation>Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002 Feb;35(2):373-9.</citation>
    <PMID>11826411</PMID>
  </reference>
  <reference>
    <citation>Ray K. NAFLD-the next global epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):621. doi: 10.1038/nrgastro.2013.197.</citation>
    <PMID>24185985</PMID>
  </reference>
  <reference>
    <citation>Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Feb 21;20(7):1712-23. doi: 10.3748/wjg.v20.i7.1712. Review.</citation>
    <PMID>24587650</PMID>
  </reference>
  <reference>
    <citation>Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005 Sep;42(3):641-9.</citation>
    <PMID>16116629</PMID>
  </reference>
  <reference>
    <citation>Review Team, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, Peñaranda MM, Ramos JF, Sarin S, Stimac D, Thomson AB, Umar M, Krabshuis J, LeMair A; World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014 Jul;48(6):467-73. doi: 10.1097/MCG.0000000000000116.</citation>
    <PMID>24921212</PMID>
  </reference>
  <reference>
    <citation>Khanna S, Patel V, Rink C, Roy S, Sen CK. Delivery of orally supplemented alpha-tocotrienol to vital organs of rats and tocopherol-transport protein deficient mice. Free Radic Biol Med. 2005 Nov 15;39(10):1310-9.</citation>
    <PMID>16257640</PMID>
  </reference>
  <reference>
    <citation>Khanna S, Rink C, Ghoorkhanian R, Gnyawali S, Heigel M, Wijesinghe DS, Chalfant CE, Chan YC, Banerjee J, Huang Y, Roy S, Sen CK. Loss of miR-29b following acute ischemic stroke contributes to neural cell death and infarct size. J Cereb Blood Flow Metab. 2013 Aug;33(8):1197-206. doi: 10.1038/jcbfm.2013.68. Epub 2013 May 1.</citation>
    <PMID>23632968</PMID>
  </reference>
  <reference>
    <citation>Khanna S, Roy S, Slivka A, Craft TK, Chaki S, Rink C, Notestine MA, DeVries AC, Parinandi NL, Sen CK. Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke. 2005 Oct;36(10):2258-64. Epub 2005 Sep 15.</citation>
    <PMID>16166580</PMID>
  </reference>
  <reference>
    <citation>Park HA, Kubicki N, Gnyawali S, Chan YC, Roy S, Khanna S, Sen CK. Natural vitamin E α-tocotrienol protects against ischemic stroke by induction of multidrug resistance-associated protein 1. Stroke. 2011 Aug;42(8):2308-14. doi: 10.1161/STROKEAHA.110.608547. Epub 2011 Jun 30.</citation>
    <PMID>21719775</PMID>
  </reference>
  <reference>
    <citation>Patel V, Khanna S, Roy S, Ezziddin O, Sen CK. Natural vitamin E alpha-tocotrienol: retention in vital organs in response to long-term oral supplementation and withdrawal. Free Radic Res. 2006 Jul;40(7):763-71.</citation>
    <PMID>16984003</PMID>
  </reference>
  <reference>
    <citation>Rink C, Christoforidis G, Khanna S, Peterson L, Patel Y, Khanna S, Abduljalil A, Irfanoglu O, Machiraju R, Bergdall VK, Sen CK. Tocotrienol vitamin E protects against preclinical canine ischemic stroke by inducing arteriogenesis. J Cereb Blood Flow Metab. 2011 Nov;31(11):2218-30. doi: 10.1038/jcbfm.2011.85. Epub 2011 Jun 15.</citation>
    <PMID>21673716</PMID>
  </reference>
  <reference>
    <citation>Gopalan Y, Shuaib IL, Magosso E, Ansari MA, Abu Bakar MR, Wong JW, Khan NA, Liong WC, Sundram K, Ng BH, Karuthan C, Yuen KH. Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter. Stroke. 2014 May;45(5):1422-8. doi: 10.1161/STROKEAHA.113.004449. Epub 2014 Apr 3.</citation>
    <PMID>24699052</PMID>
  </reference>
  <reference>
    <citation>Khosla P, Patel V, Whinter JM, Khanna S, Rakhkovskaya M, Roy S, Sen CK. Postprandial levels of the natural vitamin E tocotrienol in human circulation. Antioxid Redox Signal. 2006 May-Jun;8(5-6):1059-68.</citation>
    <PMID>16771695</PMID>
  </reference>
  <reference>
    <citation>Mahipal A, Klapman J, Vignesh S, Yang CS, Neuger A, Chen DT, Malafa MP. Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemother Pharmacol. 2016 Jul;78(1):157-65. doi: 10.1007/s00280-016-3048-0. Epub 2016 Jun 8.</citation>
    <PMID>27278668</PMID>
  </reference>
  <reference>
    <citation>Mangialasche F, Solomon A, Kåreholt I, Hooshmand B, Cecchetti R, Fratiglioni L, Soininen H, Laatikainen T, Mecocci P, Kivipelto M. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Exp Gerontol. 2013 Dec;48(12):1428-35. doi: 10.1016/j.exger.2013.09.006. Epub 2013 Oct 7.</citation>
    <PMID>24113154</PMID>
  </reference>
  <reference>
    <citation>Meganathan P, Jabir RS, Fuang HG, Bhoo-Pathy N, Choudhury RB, Taib NA, Nesaretnam K, Chik Z. A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects. Sci Rep. 2015 Sep 1;5:13550. doi: 10.1038/srep13550.</citation>
    <PMID>26323969</PMID>
  </reference>
  <reference>
    <citation>Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebti S, Malafa MP. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. EBioMedicine. 2015 Nov 14;2(12):1987-95. doi: 10.1016/j.ebiom.2015.11.025. eCollection 2015 Dec.</citation>
    <PMID>26844278</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Raj Vuppalanchi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tocotrienol</keyword>
  <keyword>Vitamin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

